First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma
News
MaxCyte has begun dosing participants in a Phase 1 trial to assess its lead CAR T-cell therapy, MCY-M11, for the treatment of advanced ovarian cancer and peritoneal mesothelioma patients who failed ... Read more